CRL — Clinical Research Labs
Back to catalog
IGF-1 LR3 3ml vial label
Growth HormonePurity 99.1%
Product profile

IGF-1 LR3

Long-arginine IGF-1 analogue for anabolic-pathway research.

99.1%
Purity
Lyophilized
Form
-20°C
Storage
Research Use Only. Not for human or veterinary consumption, diagnostic, or therapeutic use.

What it is

IGF-1 LR3 is an analogue of insulin-like growth factor 1 with an N-terminal extension and Arg-3 substitution, reducing binding-protein affinity and extending half-life.

Pathway Diagram

Mechanism of Action

CRL · MOA-01

Activates IGF-1R signaling (PI3K-Akt, MAPK) with prolonged systemic availability vs. native IGF-1.

  1. Step 01
    Receptor Binding

    Peptide engages target receptor with high affinity.

  2. Step 02
    Signal Cascade

    Downstream intracellular pathways activate.

  3. Step 03
    Cellular Response

    Gene expression and protein synthesis shift.

  4. Step 04
    Observed Outcome

    Measurable change in the studied biomarker.

Primary TargetsCell proliferation studiesMyogenic differentiationGlucose uptake research

Research highlights

Long-arginine IGF-1 analogue: N-terminal extension + Arg-3 substitution.
Reduced IGFBP binding extends bioactive half-life.
Stimulates myogenic differentiation and protein synthesis in cell models.
Widely used as cell-culture supplement in regenerative research.

Pharmacology snapshot

9,200 Da
Molecular weight
~20–30 hours (vs. ~10 min IGF-1)
Half-life
SC (research)
Route (research)

Potential research applications

Cell proliferation studies
Myogenic differentiation
Glucose uptake research
Tissue culture supplementation

Case studies

In vivo7 days

Truncated IGF-1 nitrogen balance

Cohort: Rat anabolic model

Compared full-length and truncated IGF-1 on nitrogen balance.

Outcome

Truncated/long-form IGF-1 produced superior nitrogen retention vs. native.

Tomas et al., J Endocrinol 1993;137(3):413–421
Preclinical—

Recombinant IGF-1 analogues design

Cohort: Cell-based assays

Designed and characterized fusion IGF-1 analogues including LR3.

Outcome

Established receptor binding and reduced IGFBP affinity profile.

Francis et al., J Mol Endocrinol 1992;8(3):213–223
Preclinical—

IGF-1 in skeletal muscle physiology

Cohort: Multi-model synthesis

Reviewed IGF-1 role in skeletal muscle growth and repair.

Outcome

Confirmed central role of IGF-1/PI3K/Akt axis in myogenesis.

Philippou et al., In Vivo 2007;21(1):45–54
Handling Protocol

Storage Guidelines

CRL · STR-02

Lyophilized -20°C, light-protected.

Lyophilized
-20°C
Long-term, 24 months
Reconstituted
2–8°C
Refrigerated, 28 days
Light Exposure
Protect
Store in dark vial
Diluent
BAC Water
Sterile, 0.9% benzyl
Best practice — reconstitute with bacteriostatic water, swirl gently, do not shake.
Regulatory Notice

Research Disclaimer

CRL · REG-03
Research Use Only

Strictly for in-vitro laboratory and research investigations.

Not For Human Use

Not approved for diagnostic, therapeutic, or veterinary application.

Qualified Personnel

Handling restricted to licensed researchers and laboratory staff.

Warning — IGF-1 LR3 is supplied solely for legitimate laboratory research. Any administration to humans or animals is strictly prohibited and may violate federal, state, or local law. By purchasing, the researcher accepts full responsibility for safe handling, storage, and lawful use.

Document · CRL-REG-03Revision 2026.06 · Clinical Research Labs
Representative Literature

Citations & References

CRL · REF-04
  1. 01
    Tomas FM, Knowles SE, Owens PC, et al. · 1993
    Effects of full-length and truncated insulin-like growth factor-I on nitrogen balance and muscle protein metabolism
    J Endocrinol. 137(3):413–421.
    DOI · 10.1677/joe.0.1370413PMID · 8350147
  2. 02
    Francis GL, Ross M, Ballard FJ, et al. · 1992
    Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I
    J Mol Endocrinol. 8(3):213–223.
    DOI · 10.1677/jme.0.0080213PMID · 1378736
  3. 03
    Philippou A, Maridaki M, Halapas A, Koutsilieris M. · 2007
    The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology
    In Vivo. 21(1):45–54.
    PMID · 17354613
References are representative of peer-reviewed literature and are provided for research context only.
Document · CRL-REF-04Revision 2026.06 · Clinical Research Labs